| Pharmacokinetic and Clinical Implications of Dabigatran Use in Severe Renal Impairment for Stroke Prevention in Nonvalvular Atrial Fibrillation (July/August). | |
| | |
MedLine Citation:
|
PMID: 22764329 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVE:To review the literature regarding the pharmacokinetic (PK) and clinical implications of the use of dabigatran in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation (AF).DATA SOURCES:Searches of MEDLINE (2000-April 2012) and the Cochrane Database (2000-April 2012) were conducted. Key search terms included dabigatran, renal impairment, renal failure, and renal dysfunction. Additional limits included articles written in English and those involving human subjects. Bibliographic reviews were conducted to identify other pertinent data.STUDY SELECTION AND DATA EXTRACTION:Primary data were considered eligible for inclusion if they were from studies that evaluated the PKs of dabigatran inrenal impairment or the effect of renal impairment on the risk for major bleeding with dabigatran.DATA SYNTHESIS:Dabigatran is an oral direct thrombin inhibitor indicated for the prevention of stroke and systemic thromboembolism in patients with nonvalvular AF, at a dose of 150 mg twice daily. Renal elimination is responsible for approximately 80% of dabigatran's clearance; thus, dose adjustment is required for patients with severe renal impairment. The approved dosing regimen for patients with creatinine clearance 15-30 mL/min (75 mg twice daily) was derived from PK modeling studies, limiting its applicability to the clinical setting.CONCLUSIONS:At this time, there is limited evidence to support safety or efficacy outcomes with the use of dabigatran for stroke prevention in patients with severe renal impairment and nonvalvular AF. Postmarketing data and large clinical trialsare needed to determine the role of dabigatran in this population. |
| | |
Authors:
|
Diana R Mack; Jenny J Kim |
Related Documents
:
|
2307549 - Antihypertensive therapy with ketanserin: effects on central and renal hemodynamics, an... 22888269 - Morphine promotes renal pathology in sickle mice. 22439369 - Improving the fistula rate: the northwest renal network experience. 3895709 - Hyperreninemic hypertension secondary to radiation nephritis in a child. 22758399 - De novo renal cell carcinoma of native kidneys in renal transplant recipients: a single... 22851469 - Joint european league against rheumatism and european renal association-european dialys... 7521979 - Multicenter comparison of tacrolimus (fk 506) whole blood concentrations as measured by... 17327329 - Risk factors associated with the onset and progression of posttransplantation diabetes ... 10536069 - Pneumonectomy in cystic fibrosis. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-7-3 |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: - ISSN: 1542-6270 ISO Abbreviation: - Publication Date: 2012 Jul |
Date Detail:
|
Created Date: 2012-7-5 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
< School of Pharmacy, Virginia Commonwealth University, Richmond. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hemarthrosis in a Patient on Warfarin Receiving Ceftaroline: A Case Report and Brief Review of Cepha...
Next Document: Methods of reducing allogeneic blood demand in orthopedic surgery.